4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Capital Expenditures of $4.3 million for Q4 2025, up 355.32% year-over-year from $949000.0 in Q4 2024, and up 4848.35% quarter-over-quarter from -$91000.0 in Q3 2025.
4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Capital Expenditures for 6 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures rose 355.32% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.8 million (up 48.85% YoY), while the FY2025 annual figure was $4.9 million, up 30.14% from the prior year.
- Capital Expenditures grew to $4.3 million in Q4 2025 per FDMT's latest filing, from -$91000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $6.4 million in Q1 2022 and bottomed at -$8.0 million in Q3 2022.
- Historically, Capital Expenditures has averaged $903400.0 across 5 years, with a median of $633500.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 4322.76% — and 2023, when it sank 351.82%.
- 4D Molecular Therapeutics' Capital Expenditures stood at $5.1 million in 2021, then plunged by 108.63% to -$440000.0 in 2022, then tumbled by 351.82% to -$2.0 million in 2023, then surged by 147.74% to $949000.0 in 2024, then soared by 355.32% to $4.3 million in 2025.
- Business Quant data shows FDMT's Capital Expenditures at $4.3 million in Q4 2025, -$91000.0 in Q3 2025, and $557000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18,000.00 |
| Jun 30, 2026 | -18,000.00 |
| Mar 31, 2026 | 670,000.00 |
| Mar 31, 2026 | 670,000.00 |
| Dec 31, 2025 | 4.32 Mn |
| Dec 31, 2025 | 4.32 Mn |
| Sep 30, 2025 | -91,000.00 |
| Sep 30, 2025 | -91,000.00 |
| Jun 30, 2025 | 557,000.00 |
| Jun 30, 2025 | 557,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 949,000.00 |
| Dec 31, 2024 | 949,000.00 |
| Sep 30, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Jun 30, 2024 | 349,000.00 |
| Jun 30, 2024 | 349,000.00 |
| Mar 31, 2024 | 710,000.00 |
| Mar 31, 2024 | 710,000.00 |